Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A13433 | Pages: NA | Charts: NA | Tables: NA |
Adams–Oliver Syndrome (AOS) is a rare congenital genetic disease characterized by the combination of abnormality in skin development (areas of missing skin on the scalp called aplasia cutis congenita) and malformations of the hands and feet (terminal transverse limbs defects). The aplasia cutis can affect the epidermis or the skull beneath the skin. In addition, webbed fingers or toes as well as short or missing fingers or toes are the examples of terminal transverse limb abnormalities. The severity of the syndrome varies widely among people, and it can be lethal in some cases. Furthermore, additional skeletal abnormalities of the limbs, cutis marmorata telangiectatica congenita (a blood vessel disorder), pulmonary hypertension, and heart defects are all possible indications and symptoms of the syndrome. It is caused by mutations in any of six known genes. Furthermore, depending on the genetic cause, it might be inherited in an autosomal-dominant or autosomal-recessive manner
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment
drugs for COVID-19. This in turn is expected to have a significant impact on the Adams–Oliver syndrome market.
Top Impacting Factors
Increase technological advancement and new trends in artificial limbs devices have boosted the growth of this market.
In addition, rise in research & development activities to develop novel therapies for Adams–Oliver syndrome propel the market growth. Moreover, emergence of drugs used to support palliative treatment of Adams–Oliver syndrome notably contributes toward the market growth.
Furthermore, rise in awareness about health and government initiatives to improve healthcare infrastructure serves as a key driving force of the market.
However, effective treatment is unavailable due to low prevalence rate of Adams–Oliver syndrome, which is anticipated to hamper the market growth.
Market Trends
New Product Launches to Flourish the Market
In August 2020, Johnson & Johnson announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for genetic disorder and immune-mediated diseases.
Key Benefits of the Report
Questions Answered in the Adams–Oliver Syndrome Market Report
Key Market Segments
Key Market Players